KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese.

Klotho beta (KLB) mediates binding of fibroblast growth factor (FGF) 21 to the FGF receptor (FGFR). FGF21-KLB-FGFR signaling regulates multiple metabolic systems in the liver, and we hypothesized that FGF21, KLB and FGFR single-nucleotide polymorphisms (SNPs) are involved in hepatic lipid accumulation. The SNPs were detected in 1688 individuals divided into four groups: non-obese without non-alcoholic fatty liver disease (NAFLD), obese without NAFLD, non-obese with NAFLD, and obese with NAFLD. The A-allele of KLB SNP rs7670903 correlated with higher body mass index (P = 0.0005), and the A-allele frequency was higher in the obese than non-obese group (P = 0.003). The G-allele frequency of KLB rs7674434 and T-allele frequency of rs12152703 were higher in the obese with NAFLD than obese without NAFLD group (P = 0.004 and P = 0.006), but the genotype distribution between two non-obese groups did not differ. KLB rs7674434 and rs12152703 had associations with alanine aminotransferase (ALT) (P = 0.03 and P = 0.04, respectively) and gamma-glutamyltransferase (P = 0.03 and P = 0.02, respectively) levels in all subjects, but the associations were especially strong with ALT in the NAFLD group (P = 0.005 and P = 0.008, respectively). These findings suggest that KLB SNPs are related to obesity and hepatic inflammation and that they may be involved in the pathogenesis of NAFLD.

The FGF21 Receptor Signaling Complex: Klothoß, FGFR1c, and Other Regulatory Interactions.

Scientific evidence is quickly growing that establishes FGF21 as a cytokine that signals both locally and systemically to induce metabolic effects. The focus of this chapter is the receptor/co-receptor signaling complex formed by endocrine FGF21. We provide an introduction to the major components of the complex including the Klotho family of co-receptors, fibroblast growth factor receptors (FGFRs), and the fibroblast growth factor ligands, placing each in the context of its own family members while emphasizing structural features that drive interaction. We subsequently focus specifically on FGF21 signaling through FGFR1c and KLB, describing what is known about each protein's structure and how this drives protein interaction and formation of the signaling complex at the plasma membrane. We subsequently explore the stoichiometry of FGFR1c and KLB at the plasma membrane before and after the addition of FGF21 ligand, comparing how unique features of the interaction could potentially affect signaling intensity. Finally, we discuss how formation of the signaling complex is potentially regulated by other regulatory interactions, including galectins, the extracellular matrix, and co-expression of FGFR5.

Bile Acid Diarrhea: Prevalence, Pathogenesis, and Therapy

Bile acid diarrhea (BAD) is usually seen in patients with ileal Crohn's disease or ileal resection. However, 25% to 50% of patients with functional diarrhea or diarrhea-predominant irritable bowel syndrome (IBS-D) also have evidence of BAD. It is estimated that 1% of the population may have BAD. The causes of BAD include a deficiency in fibroblast growth factor 19 (FGF-19), a hormone produced in enterocytes that regulates hepatic bile acid (BA) synthesis. Other potential causes include genetic variations that affect the proteins involved in BA enterohepatic circulation and synthesis or in the TGR5 receptor that mediates the actions of BA in colonic secretion and motility. BAs enhance mucosal permeability, induce water and electrolyte secretion, and accelerate colonic transit partly by stimulating propulsive high-amplitude colonic contractions. There is an increased proportion of primary BAs in the stool of patients with IBS-D, and some changes in the fecal microbiome have been described. There are several methods of diagnosing BAD, such as 75selenium homotaurocholic acid test retention, serum C4, FGF-19, and fecal BA measurement; presently, therapeutic trials with BA sequestrants are most commonly used for diagnosis. Management involves the use of BA sequestrants including cholestyramine, colestipol, and colesevelam. FXR agonists such as obeticholic acid constitute a promising new approach to treating BAD.